TTP management consists of 3 main strategies: therapies to supply ADAMTS13, immunomodulators that target antiADAMTS13 autoantibodies, and antiVWF drugs that prevent the formation of platelet-rich microthrombi.[12] The standard treatment of TTP is PEX, which removes antiADAMTS13 neutralizing autoantibodies and harmful cytokines from the circulation and replenishes ADAMTS13.[13] Although recovery in patients with acute attacks of TTP is possible, there is an increased risk of repeated acute attacks.[14]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.